SOURCE: Illumina
DESCRIPTION:
As part of the support, Illumina pledged $20 million over four years to help strengthen sequencing technology for 20 African countries. This in-kind donation includes next-generation sequencing platforms, reagents and training support.
Phillip G. Febbo, MD, Illumina’s Chief Medical Officer, says that the urgency presented by the COVID19 pandemic has also emerged as an opportunity to tackle geographic disparities in access to sequencing. “Those challenges aren't all the same. Each country has [its] own elements of public health where sequencing can improve outcomes for patients and improve efficiencies in health care systems," he adds.
Read the full article on Nature.com here
KEYWORDS: illumina, NASDAQ: ILMN, Sequencing Technology, COVID 19, Dr. Phillip G. Febbo